Pancreatic cancer secreted targets and uses thereof

• US 7,358,231 B1
• Filed: 12/01/2006
• Issued: 04/15/2008
• Est. Priority Date: 12/01/2005
• Status: Active Grant

• Current Assignee: Applied Biosystems LLC (Thermo Fisher Scientific Incorporated)
• Original Assignee: Applera Corporation (Thermo Fisher Scientific Incorporated)
• Inventors: Domon, Bruno, McCaffey, Ian, Alving, Kim, Ruben, Steven
• Primary Examiner(s): Monshipouri; Maryam
• Application Number:
  US11/606,949
• Time in Patent Office: 501 Days
• Field of Search: 514/12, 530/350
• US Class Current: 435/7.1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney

Abstract

The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAST) and antibodies binds to PCAST. The present invention provides that PCAST is used as targets for screening agents that modulates the PCAST activities. Further the present invention provides methods for treating diseases associated with pancreas.

Claims

1. A method of assessing pancreatic cancer in an individual, the method comprising detecting a KLK11 protein, set forth as an amino acid sequence comprising SEQ ID NO:

10, in a sample from the individual, wherein the presence of the KLK11 protein is indicative of pancreatic cancer.

2. The method of claim 1, wherein the assessing comprises diagnosing pancreatic cancer.

3. The method of claim 1, wherein the assessing comprises determining an individual'"'"'s risk of developing pancreatic cancer in the future.

4. The method of claim 1, wherein the assessing comprises prognosing the future course of pancreatic cancer in an individual who has pancreatic cancer.

5. The method of claim 1, wherein the detecting comprises determining the abundance level of the KLK11 protein.

6. The method of claim 5, wherein the method further comprises comparing the abundance level of the KLK11 protein to a reference level.

7. The method of claim 6, wherein the reference level is representative of the normal abundance level of KLK11 protein in an individual who does not have pancreatic cancer.

8. The method of claim 6, wherein a difference between the abundance level of the KLK11 protein and the reference level is indicative of pancreatic cancer.

9. The method of claim 7, wherein a difference between the abundance level of the KLK11 protein and the reference level is indicative of pancreatic cancer.

10. The method of claim 1, wherein the amino acid sequence of the KLK11 protein consists of SEQ ID NO:

10.

11. The method of claim 1, wherein the KLK11 protein is detected by contacting the sample with an isolated antibody that selectively binds to the KLK11 protein and determining the extent of binding of the antibody to the KLK11 protein.

12. The method of claim 11, wherein the antibody is coupled to a detectable substance.

13. The method of claim 5, wherein the KLK11 protein is detected by contacting the sample with an isolated antibody that selectively binds to the KLK11 protein and determining the extent of binding of the antibody to the KLK11 protein.

14. The method of claim 13, wherein the antibody is coupled to a detectable substance.

15. The method of claim 1, wherein the detecting comprises determining the activity of the KLK11 protein.